OBJECTIVE: Atomoxetine is a nonstimulant medication for treating child, adolescent, and adult ADHD. This meta-analysis compared the effects in younger and older adults. METHOD: A post hoc analysis was conducted using data from two double-blind, placebo-controlled clinical trials. Data from patients aged 18-25 years were compared with data from patients older than 25 years. RESULTS: In younger adults (mean age = 21.7), atomoxetine produces greater improvement than placebo on the Conners' Adult ADHD Rating Scale's total ADHD symptom score (p = .041, effect size = .797) and the clinical global impressions severity (p = .006, effect size = 1.121). In older adults (mean age = 43.4 years), atomoxetine also produces significant benefit on the CAARS-Inv:SV (p < .001, effect size = .326) and CGI-ADHD-S (p < .001, effect size = .346). The study findings reveal response rates to be 56.4% and 47.8% for the younger and older adults, respectively (p = .188). Tolerability is similar although older adults reported more sexual side effects. CONCLUSION: Younger and older adults show similar improvements at endpoint. The effect size is higher in younger adults, but this is due primarily to greater variability of response in older patients.
OBJECTIVE:Atomoxetine is a nonstimulant medication for treating child, adolescent, and adult ADHD. This meta-analysis compared the effects in younger and older adults. METHOD: A post hoc analysis was conducted using data from two double-blind, placebo-controlled clinical trials. Data from patients aged 18-25 years were compared with data from patients older than 25 years. RESULTS: In younger adults (mean age = 21.7), atomoxetine produces greater improvement than placebo on the Conners' Adult ADHD Rating Scale's total ADHD symptom score (p = .041, effect size = .797) and the clinical global impressions severity (p = .006, effect size = 1.121). In older adults (mean age = 43.4 years), atomoxetine also produces significant benefit on the CAARS-Inv:SV (p < .001, effect size = .326) and CGI-ADHD-S (p < .001, effect size = .346). The study findings reveal response rates to be 56.4% and 47.8% for the younger and older adults, respectively (p = .188). Tolerability is similar although older adults reported more sexual side effects. CONCLUSION: Younger and older adults show similar improvements at endpoint. The effect size is higher in younger adults, but this is due primarily to greater variability of response in older patients.
Authors: Danielle C Cath; Tammy Hedderly; Andrea G Ludolph; Jeremy S Stern; Tara Murphy; Andreas Hartmann; Virginie Czernecki; Mary May Robertson; Davide Martino; A Munchau; R Rizzo Journal: Eur Child Adolesc Psychiatry Date: 2011-04 Impact factor: 4.785
Authors: Angelo Camporeale; Kathleen Ann Day; Dustin Ruff; Jody Arsenault; David Williams; Douglas K Kelsey Journal: Drug Saf Date: 2013-08 Impact factor: 5.606
Authors: Himanshu Upadhyaya; Lenard A Adler; Miguel Casas; Alexandra Kutzelnigg; David Williams; Yoko Tanaka; Jody Arsenault; Rodrigo Escobar; Albert J Allen Journal: Child Adolesc Psychiatry Ment Health Date: 2013-05-06 Impact factor: 3.033